The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer

Background: Docetaxel is the first-line treatment for castration-resistant prostate cancer (CRPC). The limited survival benefit associated with the quick emergence of resistance and systemic toxicity diminishes its efficacy in high-dose monotherapy. YK-4-279 is a small molecule inhibitor of ETV1 tha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Med Sci
Main Authors: Yu, Lin, Wu, Xiaofeng, Chen, Min, Huang, Huarong, He, Yan, Wang, Huaqian, Li, Dongli, Du, Zhiyun, Zhang, Kun, Goodin, Susan, Zheng, Xi
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5436478/
https://ncbi.nlm.nih.gov/pubmed/28553168
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/ijms.18382
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados